lactic acid has been researched along with HIV-Associated Lipodystrophy Syndrome in 70 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Poly-L-lactic acid (PLLA) is an injectable filler used for the treatment of facial fat loss secondary to HIV and aging." | 9.12 | Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. ( Hanke, CW; Redbord, KP, 2007) |
| " polylactic acid (PLA) for the treatment of facial lipoatrophy in HIV-infected adults." | 5.17 | Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE]. ( Bouchaud, O; Carbonnel, E; Dolivo, M; Girard, PM; Lafaurie, M; Loze, B; Madelaine, I; May, T; Molina, JM; Porcher, R, 2013) |
| "Poly-L-lactic acid (PLLA) is an injectable filler used for the treatment of facial fat loss secondary to HIV and aging." | 5.12 | Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging. ( Hanke, CW; Redbord, KP, 2007) |
| "Poly-L-lactic acid (PLLA) has been available to the European medical community as a treatment for Human Immunodeficiency Virus (HIV)-associated facial lipoatrophy for nearly a decade, gaining U." | 4.85 | Patient satisfaction and duration of effect with PLLA: a review of the literature. ( Goldman, MP; Palm, MD, 2009) |
| " It could be proposed that patients having one or more of these risk factors undergo regular monitoring of plasma lactate and renal function to prevent lactic acidosis." | 3.73 | Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999--2003. ( Balestre, E; Bernardin, E; Bonnet, F; Dabis, F; Neau, D; Pellegrin, JL, 2005) |
| " Patients also reported any adverse events (AEs) during the treatment period and at the recall visit." | 2.72 | Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy. ( Barton, SE; Brown, S; Lysakova, L; Moyle, GJ, 2006) |
| " No serious adverse events were reported." | 2.72 | Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience. ( Humble, G; Mest, DR, 2006) |
| "Facial lipoatrophy is a common side effect of human immunodeficiency virus treatment with highly active antiretroviral therapy." | 2.49 | Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes. ( Davison, SP; Hung, R; Iorio, ML; Shuck, J, 2013) |
| " OBJECTIVE To review the use of injectable PLLA, specifically regarding optimal injection technique that can reduce adverse events (AEs) and enhance out comes." | 2.44 | Minimizing adverse events associated with poly-L-lactic acid injection. ( Narins, RS, 2008) |
| " The safety profile of this product has been observed in four investigator-initiated clinical trials of more than 250 HIV patients and in numerous investigator reports, with no serious adverse events or infections deemed associated with the product." | 2.43 | Safety of Sculptra: a review of clinical trial data. ( Engelhard, P; Humble, G; Mest, D, 2005) |
| "8%) were discontinued due to adverse events (AEs)." | 1.40 | Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. ( Chassany, O; Christen, MO; Dolivo, M; Duracinsky, M; Goujard, C; Herrmann, S; Leclercq, P, 2014) |
| " Periodic monitoring for adverse reactions and degree of improvement were assessed by the patient, the treating physician, and a non-treating physician." | 1.33 | Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy. ( Burgess, CM; Quiroga, RM, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 58 (82.86) | 29.6817 |
| 2010's | 12 (17.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Duracinsky, M | 2 |
| Leclercq, P | 2 |
| Armstrong, AR | 1 |
| Dolivo, M | 4 |
| Mouly, F | 1 |
| Chassany, O | 2 |
| Lafaurie, M | 3 |
| Girard, PM | 1 |
| May, T | 1 |
| Bouchaud, O | 1 |
| Carbonnel, E | 1 |
| Madelaine, I | 2 |
| Loze, B | 1 |
| Porcher, R | 2 |
| Molina, JM | 3 |
| Teplica, D | 1 |
| van Rozelaar, L | 1 |
| Kadouch, JA | 1 |
| Duyndam, DA | 1 |
| Nieuwkerk, PT | 1 |
| Lutgendorff, F | 1 |
| Karim, RB | 1 |
| Wang, AS | 1 |
| Babalola, O | 1 |
| Jagdeo, J | 2 |
| Herrmann, S | 1 |
| Christen, MO | 1 |
| Goujard, C | 1 |
| Ho, D | 1 |
| Lo, A | 1 |
| Carruthers, A | 1 |
| Narins, RS | 1 |
| Fuller, J | 1 |
| Mest, DR | 3 |
| Humble, GM | 2 |
| Levy, RM | 1 |
| Redbord, KP | 2 |
| Hanke, CW | 4 |
| Ong, J | 2 |
| Clarke, A | 2 |
| White, P | 2 |
| Johnson, MA | 1 |
| Withey, S | 2 |
| Butler, PE | 2 |
| Sadick, NS | 2 |
| Carey, D | 1 |
| Baker, D | 2 |
| Petoumenos, K | 2 |
| Chuah, J | 2 |
| Rogers, GD | 2 |
| Watson, J | 1 |
| Cooper, DA | 2 |
| Emery, S | 2 |
| Carr, A | 2 |
| Burgess, CM | 2 |
| Hilton, S | 1 |
| Narciso, P | 1 |
| Bucciardini, R | 1 |
| Tozzi, V | 1 |
| Bellagamba, R | 1 |
| Ivanovic, J | 1 |
| Giulianelli, M | 1 |
| Scevola, S | 1 |
| Palummieri, A | 1 |
| Fragola, V | 1 |
| Massella, M | 1 |
| Fracasso, L | 1 |
| De Vita, R | 1 |
| Pierro, P | 1 |
| Del Maestro, A | 1 |
| Mirra, M | 1 |
| Weimer, L | 1 |
| Palm, MD | 1 |
| Goldman, MP | 1 |
| Peyasantiwong, S | 1 |
| Loutfy, MR | 1 |
| Laporte, A | 1 |
| Coyte, PC | 1 |
| Maguina, P | 1 |
| Chaar, MY | 1 |
| Nadimi, S | 1 |
| Szczerba, SM | 1 |
| Burgess, C | 1 |
| Nelson, L | 2 |
| Stewart, KJ | 2 |
| Shuck, J | 1 |
| Iorio, ML | 1 |
| Hung, R | 1 |
| Davison, SP | 2 |
| García-Benayas, T | 1 |
| Blanco, F | 1 |
| de la Cruz, JJ | 1 |
| Soriano, V | 2 |
| González-Lahoz, J | 1 |
| Miura, T | 1 |
| Goto, M | 1 |
| Hosoya, N | 1 |
| Odawara, T | 1 |
| Kitamura, Y | 1 |
| Nakamura, T | 1 |
| Iwamoto, A | 1 |
| Valantin, MA | 1 |
| Aubron-Olivier, C | 1 |
| Ghosn, J | 1 |
| Laglenne, E | 1 |
| Pauchard, M | 1 |
| Schoen, H | 1 |
| Bousquet, R | 1 |
| Katz, P | 1 |
| Costagliola, D | 1 |
| Katlama, C | 1 |
| Boix, V | 1 |
| Moyle, GJ | 2 |
| Lysakova, L | 2 |
| Brown, S | 3 |
| Sibtain, N | 1 |
| Healy, J | 1 |
| Priest, C | 1 |
| Mandalia, S | 2 |
| Barton, SE | 4 |
| Onesti, MG | 1 |
| Renzi, LF | 1 |
| Paoletti, F | 1 |
| Scuderi, N | 1 |
| Perry, CM | 1 |
| Quiroga, RM | 1 |
| Bonnet, F | 1 |
| Balestre, E | 1 |
| Bernardin, E | 1 |
| Pellegrin, JL | 1 |
| Neau, D | 1 |
| Dabis, F | 1 |
| Haugaard, SB | 2 |
| Andersen, O | 2 |
| Dela, F | 1 |
| Holst, JJ | 1 |
| Storgaard, H | 1 |
| Fenger, M | 1 |
| Iversen, J | 1 |
| Madsbad, S | 1 |
| Rudant, J | 1 |
| Sterling, JB | 1 |
| de Mendoza, C | 1 |
| Guaraldi, G | 1 |
| Orlando, G | 1 |
| De Fazio, D | 1 |
| De Lorenzi, I | 1 |
| Rottino, A | 1 |
| De Santis, G | 1 |
| Pedone, A | 1 |
| Spaggiari, A | 1 |
| Baccarani, A | 1 |
| Borghi, V | 1 |
| Esposito, R | 1 |
| Hansen, AB | 1 |
| Lindegaard, B | 1 |
| Obel, N | 1 |
| Nielsen, H | 1 |
| Gerstoft, J | 1 |
| Engelhard, P | 2 |
| Humble, G | 2 |
| Mest, D | 1 |
| Jones, D | 1 |
| Taéron, C | 1 |
| Cattelan, AM | 1 |
| Bauer, U | 1 |
| Trevenzoli, M | 1 |
| Sasset, L | 1 |
| Campostrini, S | 1 |
| Facchin, C | 1 |
| Pagiaro, E | 1 |
| Gerzeli, S | 1 |
| Cadrobbi, P | 1 |
| Chiarelli, A | 1 |
| Simamora, P | 1 |
| Chern, W | 1 |
| Bodokh, I | 1 |
| Simonet, P | 1 |
| Treacy, PJ | 1 |
| Goldberg, DJ | 1 |
| Manfredi, R | 1 |
| Calza, L | 1 |
| Chiodo, F | 1 |
| Conant, M | 1 |
| Leonard, AL | 1 |
| El-Beyrouty, C | 1 |
| Huang, V | 1 |
| Darnold, CJ | 1 |
| Clay, PG | 1 |
| Vleggaar, D | 1 |
| Lam, SM | 1 |
| Azizzadeh, B | 1 |
| Graivier, M | 1 |
| Wildemore, JK | 1 |
| Jones, DH | 1 |
| Negredo, E | 1 |
| Higueras, C | 1 |
| Adell, X | 1 |
| Martinez, JC | 1 |
| Martinez, E | 1 |
| Puig, J | 1 |
| Fumaz, CR | 1 |
| Muñoz-Moreno, JA | 1 |
| Perez-Alvarez, N | 1 |
| Videla, S | 1 |
| Estany, C | 1 |
| Cinquegrana, D | 1 |
| Gonzalez-Mestre, V | 1 |
| Clotet, B | 1 |
| Piquet, M | 1 |
| Brignol, L | 1 |
| Chatelain, B | 1 |
| Rey, D | 1 |
| Ricbourg, B | 1 |
| Meyer, C | 1 |
| Dupont, C | 1 |
| Madelaine-Chambrin, I | 1 |
| Macaux, M | 1 |
| Faure, P | 1 |
| Johnson, M | 1 |
| Timpone, J | 1 |
| Hannan, CM | 1 |
| Carey, DL | 1 |
| Easey, N | 1 |
| Machon, K | 1 |
| Thiéry, G | 1 |
| Coulet, O | 1 |
| Adam, S | 1 |
| Guyot, L | 1 |
| Môle, B | 1 |
| Kavouni, A | 1 |
| Catalan, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized, Comparative, Multicenter, Patient-blinded Trial of the Safety and Efficacy of Intradermal Injections of Polylactic Acid (Newfill TM) Versus Polyacrylamid Gel (Eutrophill) in the Treatment of Facial Lipoatrophy in HIV-infected Patients ANRS 132[NCT00383734] | Phase 3 | 148 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| Voluma Treatment of HIV Facial Lipoatrophy[NCT02342223] | Phase 1 | 20 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Psychological Morbidity and Facial Volume in HIV Lipodystrophy:[NCT01359917] | 50 participants (Actual) | Observational | 2006-08-31 | Completed | |||
| The Effect of Low-Dose Human Growth Hormone Therapy in HIV Infected Patients on Highly Active Antiretroviral Therapy (HAART)[NCT00119769] | Phase 4 | 46 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Structural Fat Grafting for Craniofacial Trauma: Repeat Fat Grafting Injection-5 Subject Cohort[NCT01822301] | 5 participants (Actual) | Interventional | 2013-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effectiveness of Voluma injections as a treatment for HIV-associated lipoatrophy over 12 months by assessing changes in the Carruthers Lipoatrophy Severity Scale (CLSS) based on pre/post intervention photography by principal investigator (PI). CLSS is a 4-point grading scale (1 to 4, with a greater number indicating higher severity of HIV FLA). Grade 1: mild and localized facial lipoatrophy. Grade 2: deeper and longer atrophy, with the facial muscles beginning to show through. Grade 3: atrophic area is even deeper and wider, with the muscles clearly showing. Grade 4: lipoatrophy covers a wide area, extending up toward the eye sockets, and the facial skin lies directly on the muscles. (NCT02342223)
Timeframe: Baseline to 12 months
| Intervention | Participants (Number) |
|---|---|
| Voluma | 19 |
To evaluate the effectiveness of Voluma injections as a treatment for HIV-associated facial lipoatrophy over 12 months by assessing changes in the Global Aesthetic Improvement Scale (GAIS) based on pre- and post- treatment photography by participants. (NCT02342223)
Timeframe: Baseline to 12 months
| Intervention | Participants (Number) |
|---|---|
| Voluma | 19 |
"To evaluate the effectiveness of Voluma injections as a treatment for HIV-associated facial lipoatrophy over 12 months by assessing changes in the Global Aesthetic Improvement Scale (GAIS) based on pre- and post-treatment photography by principal investigator (PI). GAIS is a 5-point rating scale, ranging from worse, no change, improved, much improved, and very much improved." (NCT02342223)
Timeframe: Baseline to 12 months
| Intervention | participants (Number) |
|---|---|
| Voluma | 19 |
"To evaluate the effects of Voluma injections on the subject's quality of life (QOL) using the Dermatology Life Quality Index (DLQI). The DLQI is a validated 10-item questionnaire encompassing six different domains of QOL, including symptoms and feelings, daily activities, leisure, work/school, personal relationships, and treatment. Each question has four possible responses: not at all/not relevant, a little, a lot, and very much that corresponds to scores of 0, 1, 2, and 3, respectively, and a higher score suggests a higher level of QOL impairment. DLQI total score may range between 0 to 30." (NCT02342223)
Timeframe: Baseline to 12 months
| Intervention | scores on a scale (Mean) | |
|---|---|---|
| Baseline | 12-months post-treatment | |
| Voluma | 1.6 | 0.5 |
To evaluate the safety of Voluma injections as a treatment for HIV-associated facial lipoatrophy over 12 months by monitoring the incidence of adverse events (patient will keep a daily diary for initial 1 month and weekly phone calls will be made by study coordinator for initial 1 month to document possible adverse events, including injection site reactions, redness, bruising, swelling, and induration). (NCT02342223)
Timeframe: 12 months
| Intervention | percentage of total participants (Number) | ||||
|---|---|---|---|---|---|
| Ecchymosis | Edema | Tenderness | Pain | Permanent Treatment Related AE | |
| Voluma | 42 | 47 | 21 | 42 | 0 |
To evaluate the benefits and effects of Voluma injections on HIV-associated facial lipoatrophy as evidenced by the subject satisfaction questionnaire. (NCT02342223)
Timeframe: 12 months
| Intervention | percentage of total participants (Number) | ||
|---|---|---|---|
| "Has this treatment been beneficial to you?" | "Would you get this treatment again?" | "Would you recommend this treatment to others?" | |
| Voluma | 100 | 100 | 100 |
the facial volume and appearance grading scale evaluates each aesthetic region in the face based on both physical examination and 3D photography by the clinician. scale ranges from 1-3 where a score of 1 indicates an obvious contour defect; 2 shows a noticeable improvement in contour but not sufficient to impart a normal appearance; 3 represents a normal appearance and/or close approximation with a normal uninjured contralateral structure. (NCT01822301)
Timeframe: assessed at baseline (pre-op), days 7-21 post-op, 3 months post-op, and 9 months post-op
| Intervention | units on a scale (Mean) |
|---|---|
| Facial Volume Score at Baseline | 1.8 |
| Facial Volume Score at 7-21 Day PO | 2.2 |
| Facial Volume Score at 3 Month PO | 2.2 |
| Facial Volume Score at 9 Months PO | 2.6 |
serial computed tomography images were collected to evaluate the volume of the defect (NCT01822301)
Timeframe: assessed at 7-21 days, 3 months and 9 months post op.
| Intervention | volume, mL (Mean) |
|---|---|
| CT Imaging at 7-21 Days PO | 15 |
| CT Imaging at 3 Months PO | 10.3 |
| CT Imaging at 9 Months PO | 12.4 |
15 reviews available for lactic acid and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA).
Topics: Cosmetic Techniques; Cost-Benefit Analysis; Dermal Fillers; Esthetics; Face; Female; HIV-Associated | 2015 |
Minimizing adverse events associated with poly-L-lactic acid injection.
Topics: Cellulose; Cosmetic Techniques; Drug Compounding; Face; Female; Granuloma, Foreign-Body; HIV-Associa | 2008 |
The impact of cosmetic interventions on quality of life.
Topics: Acrylic Resins; Biocompatible Materials; Botulinum Toxins, Type A; Clinical Trials as Topic; Cosmeti | 2008 |
Patient satisfaction and duration of effect with PLLA: a review of the literature.
Topics: Adipose Tissue; Atrophy; Cosmetic Techniques; Face; Female; HIV-Associated Lipodystrophy Syndrome; H | 2009 |
The evolution of injectable poly-L-lactic acid from the correction of HIV-related facial lipoatrophy to aging-related facial contour deficiencies.
Topics: Clinical Trials as Topic; Cosmetic Techniques; Face; HIV-Associated Lipodystrophy Syndrome; Humans; | 2011 |
Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
Topics: Adipose Tissue; Cosmetic Techniques; Face; HIV-Associated Lipodystrophy Syndrome; Humans; Hyaluronic | 2013 |
Poly-L-lactic acid.
Topics: Adipose Tissue; Biocompatible Materials; Delayed-Action Preparations; Dose-Response Relationship, Dr | 2004 |
The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals.
Topics: Acidosis, Lactic; Anti-HIV Agents; Antiviral Agents; DNA Damage; DNA, Mitochondrial; Hepatitis C; HI | 2005 |
Safety of Sculptra: a review of clinical trial data.
Topics: Antiretroviral Therapy, Highly Active; Biocompatible Materials; Clinical Trials as Topic; Cosmetic T | 2005 |
HIV facial lipoatrophy: causes and treatment options.
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Collagen; Face; Fasc | 2005 |
Poly-L-lactic acid: an overview.
Topics: Absorbable Implants; Animals; Biocompatible Materials; Clinical Trials as Topic; Cosmetic Techniques | 2006 |
Poly-L-lactic acid for treating HIV-associated facial lipoatrophy: a review of the clinical studies.
Topics: Clinical Trials as Topic; Face; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome | 2006 |
Toxic metabolic syndrome associated with HAART.
Topics: Adiponectin; Adipose Tissue; Animals; Antiretroviral Therapy, Highly Active; Bone Diseases, Metaboli | 2006 |
Poly-L-lactic acid for facial lipoatrophy in HIV.
Topics: Face; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Injections, Subcutaneous | 2006 |
Poly-L-lactic acid: a perspective from my practice.
Topics: Absorbable Implants; Aging; Biocompatible Materials; Cosmetic Techniques; Face; Hand; HIV-Associated | 2008 |
13 trials available for lactic acid and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
Polylactic acid vs. polyacrylamide hydrogel for treatment of facial lipoatrophy: a randomized controlled trial [Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS) 132 SMILE].
Topics: Acrylic Resins; Adult; Aged; Anti-HIV Agents; Face; Female; HIV; HIV Infections; HIV-Associated Lipo | 2013 |
Treatment of HIV lipoatrophy and lipoatrophy of aging with poly-L-lactic acid: a prospective 3-year follow-up study.
Topics: Aged; Aging; Cellulose; Cohort Studies; Female; Follow-Up Studies; HIV-Associated Lipodystrophy Synd | 2008 |
Poly-l-lactic acid for HIV-1 facial lipoatrophy: 48-week follow-up.
Topics: Adult; Cosmetic Techniques; Face; Female; Follow-Up Studies; HIV-1; HIV-Associated Lipodystrophy Syn | 2009 |
Immediate versus delayed surgical intervention for reconstructive therapy of HIV-associated facial lipoatrophy: a randomized open-label study.
Topics: Acrylic Resins; Adult; Aged; Drug-Related Side Effects and Adverse Reactions; Female; Gels; HIV Infe | 2009 |
Psychological morbidity and facial volume in HIV lipodystrophy: quantification of treatment outcome.
Topics: Acrylic Resins; Adipose Tissue; Adult; Body Image; Cellulose; Face; Female; HIV-Associated Lipodystr | 2012 |
A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection.
Topics: Administration, Cutaneous; Adult; Antiretroviral Therapy, Highly Active; Anxiety; CD4 Lymphocyte Cou | 2004 |
Use of polylactic acid in face lipodystrophy in HIV positive patients undergoing treatment with antiretroviral drugs (HAART).
Topics: Adult; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Face; Female; HIV Infections; | 2004 |
Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Facial Dermatoses; Female; Follow-Up Studies; HIV Infe | 2005 |
Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.
Topics: Acrylic Resins; Adipose Tissue; Adult; Facial Dermatoses; Female; HIV Infections; HIV-Associated Lip | 2005 |
Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy.
Topics: Adult; Biocompatible Materials; Cosmetic Techniques; Drug Implants; Face; Female; Follow-Up Studies; | 2006 |
Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: the US experience.
Topics: Adult; Aged; Biocompatible Materials; Cosmetic Techniques; Face; HIV-Associated Lipodystrophy Syndro | 2006 |
Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging.
Topics: Adult; Aged; Aged, 80 and over; Aging; Case-Control Studies; Drug-Related Side Effects and Adverse R | 2007 |
A randomized, multicenter, open-label study of poly-L-lactic acid for HIV-1 facial lipoatrophy.
Topics: Face; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Lactic Acid; Male; Middle Aged; Polyest | 2007 |
42 other studies available for lactic acid and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
A longitudinal evaluation of the impact of a polylactic acid injection therapy on health related quality of life amongst HIV patients treated with anti-retroviral agents under real conditions of use.
Topics: Adult; Anti-Retroviral Agents; Cellulose; Face; Female; HIV Infections; HIV-Associated Lipodystrophy | 2013 |
Discussion: Autologous fat grafting and injectable dermal fillers for human immunodeficiency virus-associated facial lipodystrophy: a comparison of safety, efficacy, and long-term treatment outcomes.
Topics: Adipose Tissue; Cosmetic Techniques; Face; HIV-Associated Lipodystrophy Syndrome; Humans; Hyaluronic | 2013 |
Semipermanent filler treatment of HIV-positive patients with facial lipoatrophy: long-term follow-up evaluating MR imaging and quality of life.
Topics: Adult; Aged; Biocompatible Materials; Cosmetic Techniques; Durapatite; Face; Female; HIV Seropositiv | 2014 |
The "smile-and-fill" injection technique: a dynamic approach to midface volumization.
Topics: Cosmetic Techniques; Face; HIV-Associated Lipodystrophy Syndrome; Humans; Lactic Acid; Male; Middle | 2014 |
Safety of poly-L-lactic acid (New-Fill®) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients.
Topics: Adult; CD4 Lymphocyte Count; Cellulose; Face; Female; France; HIV Infections; HIV-Associated Lipodys | 2014 |
A 39-year-old man with HIV-associated lipodystrophy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Body Image; | 2008 |
Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
Topics: HIV-Associated Lipodystrophy Syndrome; Humans; Injections; Lactic Acid; Male; Middle Aged; Polyester | 2009 |
Objective evidence for the use of polylactic acid implants in HIV-associated facial lipoatrophy using three-dimensional surface laser scanning and psychological assessment.
Topics: Adult; Aged; Anxiety; Body Image; Cheek; Depression; Esthetics; Face; Follow-Up Studies; HIV-Associa | 2009 |
Retreatment with injectable poly-l-lactic acid for HIV-associated facial lipoatrophy: 24-month extension of the Blue Pacific study.
Topics: Adult; Aged; Biocompatible Materials; Cosmetic Techniques; Female; Follow-Up Studies; HIV-Associated | 2009 |
Poly-l-lactic acid for correction of localized facial lipoatrophy in an otherwise healthy young woman.
Topics: Dental Implants; Face; Female; Follow-Up Studies; HIV-Associated Lipodystrophy Syndrome; Humans; Inj | 2009 |
Treatment of facial lipoatrophy in HIV-infected patients.
Topics: Adipose Tissue; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as To | 2008 |
[Treatment of facial lipatrophy].
Topics: Adipose Tissue; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Cheek; Durapatite; H | 2009 |
An economic evaluation of treatments for HIV-associated facial lipoatrophy: a cost-utility analysis.
Topics: Adipose Tissue; Atrophy; Cost-Benefit Analysis; Face; HIV-Associated Lipodystrophy Syndrome; Humans; | 2010 |
Subcision with a wire dissector as an approach to human immunodeficiency virus lipoatrophy.
Topics: Atrophy; Face; HIV-Associated Lipodystrophy Syndrome; Humans; Injections; Lactic Acid; Male; Middle | 2010 |
Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Dideoxynucleosi | 2003 |
Depletion of mitochondrial DNA in HIV-1-infected patients and its amelioration by antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Therapy, Combination; Female; | 2003 |
Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA.
Topics: Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Drug Implants | 2003 |
Polylactic acid implants. A new smile for lipoatrophic faces?
Topics: Antiretroviral Therapy, Highly Active; Biocompatible Materials; Drug Implants; Facial Dermatoses; HI | 2003 |
FDA approves lipoatrophy filler.
Topics: Cellulose; Cosmetic Techniques; Drug Approval; HIV-Associated Lipodystrophy Syndrome; Humans; Lactic | 2004 |
Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Biocompatible Materials; Cosmetic Techniques; Dr | 2005 |
Risk factors for hyperlactataemia in HIV-infected patients, Aquitaine Cohort, 1999--2003.
Topics: Acidosis, Lactic; Acquired Immunodeficiency Syndrome; Adult; Age Factors; Anti-HIV Agents; CD4 Antig | 2005 |
Defective glucose and lipid metabolism in human immunodeficiency virus-infected patients with lipodystrophy involve liver, muscle tissue and pancreatic beta-cells.
Topics: Adult; Alanine; Antiretroviral Therapy, Highly Active; Blood Glucose; Body Composition; Cholesterol, | 2005 |
Poly-L-lactic acid as a facial filler.
Topics: Biocompatible Materials; Facial Hemiatrophy; HIV-Associated Lipodystrophy Syndrome; Humans; Lactic A | 2005 |
Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
Topics: Absorptiometry, Photon; Adult; Anthropometry; Anti-HIV Agents; Antiretroviral Therapy, Highly Active | 2006 |
[L-polylactic acid].
Topics: Contraindications; Face; HIV-Associated Lipodystrophy Syndrome; Humans; Injections, Intradermal; Lac | 2005 |
Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy.
Topics: Adult; Aged; Anti-Retroviral Agents; Biocompatible Materials; Drug Therapy, Combination; Face; Femal | 2006 |
[Polylactic acid injections (Newfill) in the treatment of facial lipodystrophy in HIV-positive patients].
Topics: Adult; Cosmetic Techniques; Dermis; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Injection | 2006 |
Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs.
Topics: Adult; Aged; Anti-Retroviral Agents; Biopolymers; Cosmetic Techniques; Face; Female; Follow-Up Studi | 2006 |
[Hyperlactacidemia during antiretroviral therapy: frequency and clinical-therapeutic correlations].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Comorbidity; Dy | 2006 |
Surgical Pearl: The use of a laboratory vortex for poly-L-lactic acid injection.
Topics: Biocompatible Materials; Equipment and Supplies; Equipment Design; HIV-Associated Lipodystrophy Synd | 2006 |
Soft-tissue augmentation and the role of poly-L-lactic acid.
Topics: Adult; Aged; Aged, 80 and over; Biocompatible Materials; Cicatrix; Cosmetic Techniques; Face; Female | 2006 |
Injectable poly-L-lactic acid (Sculptra): technical considerations in soft-tissue contouring.
Topics: Adult; Aged; Biocompatible Materials; Cellulose; Cheek; Cosmetic Techniques; Face; Female; Freeze Dr | 2006 |
Persistent granulomatous inflammatory response induced by injectable poly-L-lactic acid for HIV lipoatrophy.
Topics: Biocompatible Materials; Diagnosis, Differential; Face; Granuloma, Foreign-Body; HIV-Associated Lipo | 2006 |
Reconstructive treatment for antiretroviral-associated facial lipoatrophy: a prospective study comparing autologous fat and synthetic substances.
Topics: Acrylic Resins; Adipose Tissue; Adult; Anti-Retroviral Agents; Cosmetic Techniques; Face; Female; Fo | 2006 |
[Polylactic acid injections: usefullness for the treatment of facial lipoatrophy in HIV+ patients under tritherapy].
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Biocompatible Materials; Body Mass I | 2007 |
[Traceability of a resorbable implant for lipoatrophy: why should it be traced and how should this be done? Example of polylactic acid (Newfill)].
Topics: Absorbable Implants; Face; Female; HIV-Associated Lipodystrophy Syndrome; Humans; Lactic Acid; Male; | 2007 |
Experience in the treatment of HIV-associated lipodystrophy.
Topics: Acrylic Resins; Adipose Tissue; Algorithms; Face; Female; Follow-Up Studies; HIV-Associated Lipodyst | 2008 |
Does severity predict distress? The relationship between subjective and objective measures of appearance and psychological adjustment, during treatment for facial lipoatrophy.
Topics: Adaptation, Psychological; Adult; Aged; Antiretroviral Therapy, Highly Active; Anxiety; Body Image; | 2007 |
Surgical algorithm for management of HIV lipodystrophy.
Topics: Adipose Tissue; Adult; Algorithms; Back; Cellulose; Disease Progression; Face; Gynecomastia; HIV-Ass | 2007 |
[Poly-L-lactic-acid filling of facial lipoatrophy in HIV+ patients under tritherapy].
Topics: Antiretroviral Therapy, Highly Active; Biocompatible Materials; Cellulose; Cosmetic Techniques; Face | 2008 |
[Long-lasting filling procedures].
Topics: Acrylates; Acrylic Resins; Biocompatible Materials; Cellulose; Cosmetic Techniques; Durapatite; HIV- | 2008 |
The face of HIV and AIDS: can we erase the stigma?
Topics: Adult; Biocompatible Materials; Cosmetic Techniques; Female; HIV-Associated Lipodystrophy Syndrome; | 2008 |